Changes in Hong Kong stocks | Danno Pharmaceutical-B (06872) rose more than 7% and was included in the Hong Kong Stock Connect list recently, rifuquinone phase IIa proof of concept data is positive

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Danuo Pharmaceutical-B (06872) rose more than 7%. The stock surged higher than 15% yesterday, then dived down more than 8%. As of press release, it rose 7.45% to HK$165.8, with a turnover of HK$27.412,800.

According to the news, since September 7, Danno Pharmaceuticals has officially been included in the Hong Kong Stock Connect list. The company said that being included in the Hong Kong Stock Connect this time is the capital market's full recognition of the company's investment value, market capitalization size and liquidity. Mainland Chinese investors who meet the relevant qualifications can directly invest in company shares through the Shanghai-Shenzhen-Hong Kong Stock Connect mechanism.

Danno Pharmaceuticals focuses on bacterial infections and diseases related to bacterial metabolism. Relying on a self-developed multi-target conjugated molecular technology platform, the company has established 7 innovative pipelines. The core products include rifonidazole (TNP-2198) and rifuquinone (TNP-2092 injections). On September 7, Danno Pharmaceuticals announced that the phase IIa proof-of-of-concept clinical trial of rifoquinone to treat artificial joint infections (PJI) has achieved positive results, and a multi-center phase IIb trial has begun.